AbbVie Advances Crohn’s Disease Treatment with New Clinical Study

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.

AbbVie is conducting a Phase 2a study titled ‘A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn’s Disease.’ The study aims to evaluate the effectiveness and safety of targeted therapies in adults with moderate to severe Crohn’s disease, a chronic inflammatory condition of the digestive tract. This research is significant as current treatments may not work for all patients or lose effectiveness over time.

The study is testing three drugs: Risankizumab, ABBV-382, and Lutikizumab. These are administered as injections or infusions, aiming to reduce inflammation and manage symptoms in patients. The study includes multiple treatment arms, with some participants receiving monotherapy while others receive combination therapies.

This interventional study is randomized and follows a sequential intervention model, focusing on treatment as its primary purpose. There is no masking involved, meaning both researchers and participants know which treatments are being administered.

The study began on September 4, 2024, with primary completion expected in 2025. The last update was submitted on June 30, 2025. These dates are crucial as they indicate the study’s progress and timelines for potential results.

AbbVie’s study could influence its stock performance positively if the results show significant efficacy and safety, potentially boosting investor confidence. The study’s outcome may also impact the competitive landscape in the treatment of Crohn’s disease, where effective new therapies are in demand.

The study is ongoing, with further details available on the ClinicalTrials portal.